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Macrophages activated by the TLR4 agonist LPS un-
dergo dramatic changes in their metabolic activity.
We here show that LPS induces expression of
the key metabolic regulator Pyruvate Kinase M2
(PKM2). Activation of PKM2 using two well-charac-
terized small molecules, DASA-58 and TEPP-46, in-
hibited LPS-induced Hif-1a and IL-1b, as well as
the expression of a range of other Hif-1a-dependent
genes. Activation of PKM2 attenuated an LPS-
induced proinflammatory M1 macrophage pheno-
type while promoting traits typical of an M2
macrophage. We show that LPS-induced PKM2 en-
ters into a complex with Hif-1a, which can directly
bind to the IL-1b promoter, an event that is inhibited
by activation of PKM2. Both compounds inhibited
LPS-induced glycolytic reprogramming and succi-
nate production. Finally, activation of PKM2 by
TEPP-46 in vivo inhibited LPS and Salmonella typhi-
murium-induced IL-1b production, while boosting
production of IL-10. PKM2 is therefore a critical
determinant of macrophage activation by LPS, pro-
moting the inflammatory response.
INTRODUCTION
Insights into the critical role of metabolic reprogramming in host
defense and inflammation have recently emerged (Krawczyk
et al., 2010; O’Neill and Hardie, 2013). In macrophages activated
with the TLR4 agonist LPS, there is a high demand for biosyn-
thetic precursors for proteins, lipids, and nucleic acids as wellCas increased energy demand. These events are required for
the cells to respond to infection or tissue injury during inflamma-
tion. The metabolic changes that occur resemble the well-
describedWarburg effect (also known as aerobic glycolysis) first
reported in tumor cells (Altenberg and Greulich, 2004; Warburg,
1923). These alterations include increased glucose uptake, an
elevated rate of glycolysis, and an upregulated pentose phos-
phate pathway in conjunction with a reduced level of oxidative
phosphorylation via the tricarboxylic acid (TCA) cycle (Tannahill
et al., 2013).
Increased levels of the TCA cycle intermediate succinate as a
consequence of this metabolic switch in highly glycolytic acti-
vated ‘‘M1’’ macrophages has revealed that succinate facilitates
the signal leading to stabilization of hypoxia inducible factor-1a
(Hif-1a) (Koivunen et al., 2007; Tannahill et al., 2013). This phe-
nomenon, which has been described as ‘‘pseudo hypoxia,’’
takes place when excess succinate is transported out of the
mitochondria into the cytosol, where it can impair the activity
of prolylhydroxylases (PHD), leading to stabilization and activa-
tion of Hif-1a (Selak et al., 2005). Hif-1a then positively regulates
the proinflammatory cytokine IL-1b and other Hif-dependent
genes including those encoding enzymes in glycolysis (Tannahill
et al., 2013).
There is only limited information on the precise molecular de-
terminants of this profound change in metabolism.
Numerous studies have reported a key role for PKM2 in aero-
bic glycolysis of tumors (Christofk et al., 2008; Mazurek et al.,
2005; Tamada et al., 2012). Mammalian cells contain two PK
genes. One encodes PKL and PKR, which are exclusively ex-
pressed in liver and red blood cells, respectively. The second
gene encodes PKM1 and PKM2. These are generated by exclu-
sive alternative splicing of the Pkm pre-mRNA (Chen et al., 2012;
Takenaka et al., 1991). In glycolysis, pyruvate kinase is the rate-
limiting enzyme that converts phosphoenolpyruvic acid (PEP) to
pyruvate, a reaction that in differentiated tissue is mediated byell Metabolism 21, 65–80, January 6, 2015 ª2015 Elsevier Inc. 65
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the enzymatically active isoform PKM1. PKM2 on the other hand
is upregulated in tumors (Altenberg and Greulich, 2004) and ex-
ists primarily as an enzymatically inactivemonomer or dimer. The
PKM2 dimer can translocate to the nucleus, where it will interact
with Hif-1a and regulate expression of numerous proglycolytic
enzymes (Luo et al., 2011), an event that is dependent on
ERK1/2 activity and regulated by Jumoji C domain-containing di-
oxygenase (JMJD5) (Wang et al., 2014; Yang et al., 2012). Other
nuclear functions of dimeric PKM2 include the ability to act as a
protein kinase, activating transcription of mek5 through phos-
phorylation of STAT3 (Gao et al., 2012), as well as promoting
b-catenin translocation, leading to expression of cyclinD1 and
c-myc (Yang et al., 2011). Current evidence indicates that nu-
clear PKM2 thereby drives the Warburg effect in tumors (Yang
and Lu, 2013).
The enzymatic pyruvate kinase activity of PKM2 can be allo-
sterically triggered endogenously by fructose-1,6-bisphosphate
(FBP), serine, and succinylaminoimidazolecarboxamide ribose-
50-phosphate (SAICAR) (Chaneton et al., 2012; Jurica et al.,
1998; Keller et al., 2012). PKM2 can also be activated using
the highly specific small-molecule activators DASA 58 and
TEPP-46 (Anastasiou et al., 2012). These will bind PKM2-pro-
moting tetramers to form, leading to an enzyme with a high pyru-
vate kinase activity, allowing PKM2 to mediate the last step of
glycolysis by promoting the flux through glycolysis.
We provide evidence here for PKM2 induction in response to
LPS inmacrophages. This event is required formacrophage acti-
vation by LPS and we identify PKM2 as a critical modulator of
IL-1b production, macrophage polarization, glycolytic reprog-
ramming, and Warburg metabolism in LPS-activated macro-
phages. PKM2 therefore presents itself as a therapeutic target
in both cancer and inflammation.
RESULTS
Tetramerization of PKM2 Using Small-Molecule
Activators Inhibits LPS-Induced Activation of Primary
Bone Marrow-Derived Macrophages
We hypothesized that, similar to tumor cells, PKM2 would be
required for Warburg metabolism in LPS-activated macro-
phages. LPS induced high levels of PKM2 in bone marrow-
derived macrophages (BMDMs) up to 48 hr (Figure 1A).
Disuccinimidyl suberate (DSS) crosslinking of lysates from
LPS-treated BMDMs suggest that LPS-induced PKM2 is primar-
ily of a monomeric configuration (Figure 1B). Furthermore, LPSFigure 1. Tetramerization of LPS-Induced PKM2 in Primary BMDMs In
(A and C) LPS-stimulated BMDMs were assayed for expression of PKM2, Y105-p
qRT-PCR (C).
(B) Crosslinking (500 mM DSS) and western blot of endogenous PKM2 in BMDM
(D) LPS did not significantly affect expression of PKM1 in BMDMs.
(E) BMDMs pretreated with ±DASA-58 or ±TEPP-46 as indicated, followed by LP
Lamin A, and Tubulin were detected by western blotting.
(F) DSS crosslinking and western blotting of PKM2 in BMDMs and RAW macrop
(G) RAW macrophages treated with ±10 mM TEPP-58 or DMSO (1 hr), followe
for PKM2.
(H) BMDMs (left) or PECs (right) were pretreated ±DASA-58 or TEPP-46 (30 min),
IL-1b or b-actin expression by western blotting.
(I and J) Il1b (left), Il6 (middle), and Ldha (right) mRNA (I) and IL-6 (left) and TNF (righ
LPS for 6–24 hr. Data represent mean ± SEM, n = 3, **p < 0.01.
Cstrongly induced Pkm2 mRNA expression (Figure 1C), with
expression levels increasing approximately 2.8-fold after 24 hr
of LPS.
Phosphorylation of PKM2 on Tyrosine 105 is indicative of
monomer/dimer formation, as it prevents PKM2 tetramer config-
uration, further promoting the Warburg effect (Hitosugi et al.,
2009). LPS-induced expression of PKM2 causes concurrent
phosphorylation of Tyrosine 105 to an extent comparable or
greater to the increased expression levels. This phosphorylation
is evident after just 1 hr, with the strongest induction after 48 hr
(Figure 1A, middle, 10.3-fold increase in relative band intensity).
This phosphorylation event suggests that PKM2 in LPS-acti-
vated macrophages primarily forms an enzymatically inactive
dimer or monomer. This is further supported by results from
the crosslinking experiments shown in Figure 1B, where DSS
crosslinked lysates from LPS-treated BMDMs failed to reveal
any high molecular weight PKM2 complexes.
Since PKM1 is the second alternatively spliced gene product
of the Pkm gene, we also examined protein expression of
PKM1 in response to LPS. As shown in Figure 1D, PKM1 expres-
sion levels did not increase substantially in response to LPS but
instead a slight decrease in PKM1 protein was observed after
24 hr of LPS, confirming that in relation to the Pkm gene, the
effect of LPS is specific to PKM2.
In order to examine the functional relevance of PKM2 for LPS
action, we next examined the effect of two highly specific small-
molecule PKM2 activators, TEPP-46 and DASA-58. These tool
compounds were used to probe PKM2 function. They promote
the formation of active PKM2 tetramers, thereby boosting
PKM2 enzymatic activity and limiting tumor growth in vivo (Anas-
tasiou et al., 2012).
We confirmed the targeting of PKM2 by DASA-58 and TEPP-
46 by assessing the effect of PKM2 activation on the subcellular
localization of PKM2. As depicted in Figure 1E, LPS caused an
increased expression level of PKM2 in the cytosol (compare
lane 7 to lane 8) as well as in the nucleus (compare lane 1 to
lane 2). However, driving PKM2 into tetramers using DASA-58
(compare lane 3-4 to lane 2) and TEPP-46 (compare lane 5-6
to lane 2) inhibited LPS-induced nuclear translocation. However,
such reduction of PKM2 in the cytosolic fraction was not evident
in response to either compound. Fractions from vehicle-treated
samples were immunoblotted for Tubulin and Lamin A to control
for preparation purity.
Since previous reports have established that PKM2 enters the
nucleus as a dimer, we then carried out further DSS crosslinkinghibits the Hif-1a Targets IL-1b and Ldha
hosphorylated PKM2, and b-actin by western blotting (A) and Pkm2mRNA by
s ± LPS (24 hr).
S for 24 hr. Cytosolic and nuclear fractions were isolated and PKM2, b-actin,
hages after treatment ±100 mM TEPP-58 or ± 50 mM DASA-46.
d by LPS. Protein separated by size exclusion chromatography and blotted
followed by stimulation with LPS for 24 hr. Cell lysates were analyzed for pro-
t) protein expression (J) weremeasured in BMDMs treated with ±DASA-58 and
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Figure 2. Activation of PKM2 Using TEPP-46 Attenuates the M1 Attributes of LPS-Activated BMDMs
BMDMs were stimulated with 100 ng/ml LPS or 20 ng/ml IL-4 for M1 and M2 polarization, respectively; 24 hr after stimulation RNA was extracted.
(A) Left to right, expression of il12-p40, cxcl-10, arginase-1, and mrc-1 were analyzed to assess differentiation into M1 and M2 macrophages.
(legend continued on next page)
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studies in order to support a model for nuclear exclusion of
PKM2 following treatment with our small-molecule activators.
RAW cells as well as primary BMDMs (Figure 1F) were treated
with TEPP-46 and DASA-58 as indicated. Lysates were cross-
linked using DSS and endogenous PKM2 was subsequently
detected. The blot clearly reveals a high molecular weight
PKM2-containing complex of approximately 250 kDa following
treatment with TEPP-46 andDASA-58, pointing to a tetramer for-
mation of PKM2. In addition, lysates from RAW cells treated with
TEPP-46 were separated through size exclusion using fast
protein liquid chromatography (FPLC) (Figure 1G). Fractions
collected were analyzed by western blotting detecting PKM2
and the result reveals a shift in the molecular weight of PKM2
with the appearance of a band corresponding to approximately
250 kDa (Figure 1G, elution volume 10–11 ml) and a reduction
of the smaller molecular weight complexes (elution volume 13–
14), again suggesting a tetrameric formation of endogenous
PKM2 following TEPP-46 treatment.
We know from a previous study that LPS-induced transcrip-
tion of the proinflammatory cytokine IL-1b is an event closely
linked to the Warburg metabolism of activated macrophages
(Tannahill et al., 2013). Hence, we next examined the effect of
activation of LPS-induced PKM2 using TEPP-46 and DASA-58
on the production of pro-IL-1b in activated BMDMs and perito-
neal cells (PECs). As shown in Figure 1H, DASA-58 and TEPP-
46 inhibited the induction of pro-IL-1b in LPS-activated BMDMs.
Both compounds also inhibited LPS-induced pro-IL-1b in PECs
(Figure 1H). As shown in Figure 1I, activation of PKM2 using
DASA-58 also inhibited LPS-induced expression of Il1b mRNA
but importantly had no effect on LPS-induced Il6 mRNA levels.
PKM2 activation also significantly inhibited LPS-induced
expression of the Hif-1a target gene Ldha. Furthermore, LPS-
induced IL-6 and TNF protein expressions (Figure 1J) were
unaffected by activation of PKM2 consistent with these cytokine
responses not directly requiring Warburg metabolism (Tannahill
et al., 2013).
To further examine the effects of the specific small-molecule
PKM2 activator in an unbiased fashion, we undertook a whole-
genome transcriptomics analysis of LPS and LPS+DASA-58-
treated BMDMs. We identified a signature set of 100 genes
(Figure S1 available online, Table S1) for which the activation
of PKM2 induced a markedly distinct response from that
observed during LPS treatment alone. A general enrichment
analysis of this gene set for biological pathways and processes
(using MetaCore) identified significant regulation in predomi-
nantly immune response pathways (Tables S2 and S3). These
included Interferon signaling, FcgR-mediated phagocytosis,
and IL4 signaling. To examine specifically for signatures of meta-
bolic pathways, we analyzed enrichment of metabolic networks
and found 48 pathways to be significantly enriched (FDR < 0.05)
with glycolysis being the top ranking metabolic pathway (Table(B) Expression of pkm2 (left) and pkm1 (right) was measured for each polarizing
(C) BMDMs were pretreated with 100 mM TEPP-46 or DMSO (1 hr), followed by L
and mrc-1 was analyzed.
(D) IL-10 expression measured in supernatants from BMDMs ± DASA-58 (50 mM,
(E) Transcriptomics data set profile GSE53053 used to identify genes that were sig
sample t test; nominal p value% 0.05, absolute log2-fold-changeR 2-fold). A chi
significant patterns from microarray data (Figure S1) comparing LPS+DASA-58 t
CS4). The key glycolytic enzymes underlying this signature are
PFKP, ALDOC, and TPI1, all three of which directly regulate
the levels of FBP in this pathway. Phosphofructokinase (PFKP),
which catalyzes the irreversible conversion of fructose-6-phos-
phate to FBP, is relatively downregulated by activation of
PKM2, whereas the enzymes downstream of this metabolite,
namely ALDOC and TPI1, are significantly upregulated by
DASA-58. This suggested that we would expect to find signifi-
cantly lower levels of FBP metabolite during PKM2 activation
compared to LPS stimulation alone. To assess candidate tran-
scription factors that are likely perturbed by activation of
PKM2, we analyzed the signature set for enrichment of target
genes of known transcription factors (TFs). We found enrichment
for several interferon-associated factors (IRF1, IRF8, ISGF3) as
well as NRF2 and Hif-1a among the top ten candidate TFs (Table
S5). Several of the well-known targets of HIF1a, such as Vimen-
tin, Plaur (uPAR), Stap1 (Art-27), Sort1, and PFKP, were either
downregulated or not expressed when BMDMs were stimulated
with LPS in the presence of DASA-58.
These results suggest that activation of PKM2 inmacrophages
inhibited LPS-induced expression of proglycolytic and Hif-1a-
dependent genes.
Activation of PKM2 Attenuates LPS-Induced M1
Macrophage Polarization in BMDMs
To further investigate the effect of activation of PKM2 on the pro-
or anti-inflammatory phenotype of activated macrophages, we
set up polarizing conditions to generate M0 (undifferentiated),
M1 (classically activated), or M2 (alternatively activated) macro-
phages as described. Figure 2A validates the polarizing condi-
tions showing an upregulation of the markers Interleukin-12 p40
(Il12p40) andC-X-C chemokine 10 (Cxcl-10) in M1macrophages
and an increased expression of Arginase-1 (Arg-1) andMannose
Receptor C, type 1 (Mrc-1) during M2 polarizing conditions. We
nextmeasured expressionof PKM2 in thesedistinctmacrophage
populations and as Figure 2B shows, PKM2 expression is upre-
gulated in M1 macrophages. In addition, we see a clear downre-
gulation of PKM1 mRNA in these M1 macrophages.
In order to examine the effect of our tool compounds on the
expression of M1 and M2 signature gene subsets, we next
treated LPS-activated M1 macrophages with TEPP-46. As
seen in Figure 2C, the expression of the M1 markers Il12p40
and Cxcl-10 are significantly downregulated following TEPP-46
treatment. Similarly, although not significant, we consistently
observed a boost in the expression of the M2 markers Arg-1
and Mrc-1 by TEPP-46 in M1-polarized macrophages.
Interestingly, activation of PKM2 boosted LPS-induced ex-
pression of the anti-inflammatory M2 cytokine Interleukin-10
(IL-10) in BMDMs (Figure 2D), further supporting an attenuation
of the M1 phenotype after activation of PKM2 in favor of a
more M2-like macrophage.condition.
PS (24 hr). RNA was extracted and expression of il12-p40, cxcl-10, arginase-1,
30 min) followed by LPS (24 hr). Data represent mean ± SEM, n = 3, **p < 0.01.
nificantly up- or downregulated inM1 or M2 polarizing conditions (two-tail two-
-square test was performed to identify sets of up- or downregulated genes with
o LPS-treated macrophages.
ell Metabolism 21, 65–80, January 6, 2015 ª2015 Elsevier Inc. 69
A B
C D
E F
Figure 3. Dimeric/Monomeric PKM2 Is
Required for LPS-Induced Binding of
PKM2 and Hif-1a to the IL-1b Promoter
(A) Immunoprecipitation of PKM2 in BMDMs
treated with LPS (24 hr). Hif-1a measured by
immunoblotting.
(B) BMDMs treated ±TEPP-46 (50 mM, 60 min)
followed by LPS (24 hr) were lysed and an OPD
assay was carried out using oligonucleotide
spanning the HIF1a binding site on the IL1b pro-
moter. Samples were probed for Hif-1a (top) and
PKM2 (bottom). Representative of n = 3.
(C and D) ChIP-PCR using PKM2 and HIF-1a an-
tibodies and primers specific for 300 position of
Il1b in LPS-treated BMDMs (C, sequential) and
BMDMs treated with TEPP-46/DASA-58 (30 min,
50 mM) and LPS (100 ng/ml, 24 hr) (D). ChIP data
are calculated as percent of input, represented as
fold binding ±SD for one representative experi-
ment (n = 3).
(E) BMDMs or (F) PECs (right) (13 106 cells per ml)
were pretreated with indicated doses of DASA-58
or TEPP-46 (30 min), followed by LPS (100 ng/ml,
24 hr). Hif-1a or b-actin expression was analyzed
by western blotting.To conclusively establish whether addition of DASA-58 prior
to LPS treatment of macrophages led to an attenuation of
LPS-induced M1 traits and these cells becoming more M2-
like, we first downloaded and analyzed a transcriptomics profile
of bone marrow-derived macrophages treated with either IL4 or
a combination of LPS+Interferon-g (IFNg) (GSE53053). Using
this data set, we identified genes that were significantly up-
or downregulated in either M1 or M2 polarizing conditions
(two-tail two-sample t test; nominal p value % 0.05, Absolute
log2-fold-change R 2-fold). Next, we used a chi-square test
to assess which set of up- or downregulated genes showed
significant patterns in our own microarray data (from Fig-
ure S1) comparing LPS+DASA-58-treated macrophages to
LPS-treated cells. We found that genes upregulated in M1 cells
were significantly upregulated by LPS treatment compared to
LPS+DASA-58 (Figure 2E). In addition to this, genes upregu-
lated in the M2 signature set were also enriched for genes
upregulated by DASA+LPS compared to LPS alone but to a
lesser extent.70 Cell Metabolism 21, 65–80, January 6, 2015 ª2015 Elsevier Inc.This effect on expression of M1 andM2
markers, together with our observation
that DASA-58 causes an increased
expression of LPS-induced IL-10 sug-
gests that activation of PKM2 in LPS-acti-
vated macrophages may help to dampen
the proinflammatory phenotype of the
cell.
LPS Promotes Binding of PKM2 and
Hif-1a to the IL-1b Promoter
PKM2 has been shown to interact with
Hif-1a and stimulate Hif-1a transactiva-
tion domain function and recruitment of
p300 to the Hif Response Element (HRE)of Hif-1a target genes (Luo et al., 2011). Treatment of BMDMs
with LPS for 24 hr increased the association of endogenous
PKM2 with endogenous Hif-1a, as shown in Figure 3A.
In order to investigate binding of PKM2 to the Hif-1a-specific
binding site of the IL-1b promoter, we next used two ap-
proaches. First we employed an oligo pull-down (OPD) assay
where an oligonucleotide specific to the Hif-1a binding site of
the IL-1b promoter (408; Tannahill et al., 2013) was incubated
with lysates from TEPP-46 and LPS-treated primary BMDMs
as indicated (Figure 3B). These results reveal binding of PKM2
to the IL-1b promoter (bottom left). In addition, there is an
increased binding of both PKM2 and Hif-1a to this promoter
site in response to LPS (compare lane 2 to lane 1). Furthermore,
tetramerization of PKM2 using TEPP-46 inhibits LPS-induced
binding of PKM2 and Hif-1a to the IL-1b promoter (compare
lane 3 to lane 2).
We extended our binding studies to include sequential chro-
matin immunoprecipitation (ChIP) assays. This technique allows
us to simultaneously examine the endogenous binding of two
transcription factors to chromatin in response to LPS. As seen in
Figure 3C, LPS causes increased binding of endogenous Hif-1a
to the IL-1b promoter (left), and interestingly after this sample
was put through a second round of ChIP specific for PKM2
(right), we also saw an increased binding of endogenous PKM2
to the same copy of DNA in response to LPS. Furthermore, acti-
vation of PKM2 using TEPP-46 and DASA-58 caused significant
inhibition of LPS-induced binding of both Hif-1a and PKM2 to the
IL-1b promoter (Figure 3D).
A role for PKM2 in LPS-induced stability of Hif-1a was further
verified by directly measuring LPS-induced Hif-1a protein as
shown in Figure 3E, where DASA-58 and TEPP-46 inhibited the
induction of Hif-1a protein in LPS-activated BMDMs. Both com-
pounds also inhibited LPS-induced Hif-1a protein in peritoneal
macrophages (Figure 3F).
PKM2 Activators Inhibit Glycolysis and the
Accumulation of Succinate in LPS-Activated
Macrophages
We next examined the metabolic consequences of PKM2 induc-
tion by LPS. We first investigated whether activation of PKM2
could inhibit LPS-induced glycolysis. BMDMs were treated
with TEPP-46 and DASA-58 prior to LPS and extracellular acid-
ification wasmonitored as shown in Figure 4A. LPS caused up to
a 10-fold increase in glycolysis, which is markedly inhibited by
both TEPP-46 and DASA-58. Neither TEPP-46 nor DASA-58
had a significant effect on oxidative phosphorylation as
measured by oxygen consumption rate (data not shown).
One important consequence of LPS-induced metabolic re-
programming in macrophages is a buildup of succinate, which
acts as an inflammatory signal contributing to increased Hif-1a
dependent IL-1b expression (Tannahill et al., 2013). In agreement
with a role for PKM2 in LPS action here, DASA-58 dramatically
blocked LPS-induced succinate (Figure 4B).
We carried out a comprehensive metabolomic profiling of
LPS-activated BMDMs in the presence or absence of DASA-
58. We revealed a clear effect of PKM2 activation by DASA-58
in preventing LPS-induced glycolysis (Figure 4C and Table S6).
LPS stimulation led to accumulation of upstream glycolytic inter-
mediates, such as glucose-6-phosphate (G6P), FBP, dihydroxy-
acetone phosphate (DHAP), and phosphoglyceric acid (2-PG),
and TCA cycle intermediates including malate, fumarate, and
succinate (Figure 4C, left; all metabolites with significant accu-
mulation [p value < 0.05] are shown in bold red text; those high-
lighted in yellow indicate upregulation following LPS stimulation).
Activation of PKM2 prevented the accumulation of any of these
glycolytic intermediates. These findings are consistent with the
microarray results in which we found evidence to suggest deple-
tion of FBP during activation of PKM2. Additionally, the pentose
phosphate pathway intermediate Ribose 5-phosphate (R5P),
was significantly accumulated in response to LPS (Figure 4C,
left); however, this was alleviated by activation of PKM2 (right).
Furthermore a significant upregulation in levels of purines and
pyrimidines downstream of the pentose phosphate pathway
(such as cytidine, inosine, and uridine) were observed in
DASA-58-treated samples (Figure 4C, right), suggesting that
PKM2 can somehow promote the process of pyridine and pyrim-
idine biosynthesis downstream of R5P. These metabolomic
changes are consistent with DASA-58 activating PKM2, whichCwould lead to a decrease in glycolytic and pentose phosphate
pathway intermediates.
Isoform-Specific Deletion of PKM2 Inhibits
LPS-Mediated Activation of Hif-1a and Expression of
Hif-1a Target Genes in Macrophages
In order to confirm a role for PKM2 in LPS signaling, we next used
BMDMs generated from mice carrying a conditional PKM2fl/fl
allele allowing for Cre-recombinase-mediated deletion (Israelsen
et al., 2013) and matched wild-type controls. Isolated BMDMs
were treatedwith ±600 nMTamoxifen for 72 hr prior to the exper-
iment in order to excise the PKM2-specific Pkm Exon 10. Pkm2
expression was successfully ablated (Figure 5A); however, as
expected, Pkm1 expression was compensatorily increased (Fig-
ure 5B). In addition, PKM2 protein levels were successfully
reduced following treatment with Tamoxifen (Figure 5C, top
panel, compare lanes 5 and 6 to lanes 7 and 8), whereas
PKM1 protein was upregulated following Tamoxifen and LPS
treatment compared to control (Figure 5C, second panel). LPS-
induced Hif-1a protein was dramatically decreased in PKM2
knockout cells compared to mock-treated cells expressing
PKM2 (Figure 5C, third panel; compare lane 2 to 4 in relation to
lane 6 to 8). Furthermore, as a functional consequence of this,
BMDMs lacking PKM2 displayed a significantly reduced mRNA
expression level of the Hif-1a-responsive genes Il1b and Ldha
in response to LPS (Figure 5D). In contrast, LPS-induced IL-6
and TNFa expression (Figure 5E) were comparable in Tamox-
ifen-treated versus mock-treated PKM2fl/fl BMDMs. This result
clearly pointed to the requirement for PKM2 in the activation of
HIF1a in response to LPS.
Using BMDMs generated from PKM2fl/fl mice, we measured
the rate of glycolysis in response to LPS. Macrophages with
diminished expression of PKM2 displayed a reduced rate of
glycolysis in response to LPS compared to cells with an intact
PKM2 gene (depicted in Figure 5F). Furthermore, BMDMs with
an impaired PKM2 gene exhibit an increased rate of oxidative
phosphorylation as measured by oxygen consumption rate
(OCR) (Figure 5F). However, although as expected LPS causes
a reduction in OCR in PKM2+/+ cells (Tannahill et al., 2013),
the same inhibitory effect was still observed in BMDMs derived
from PKM2/ cells (data not shown). Taken together, these re-
sults point to a key role for PKM2 in LPS-induced glycolysis.
In order to control for off-target effects of TEPP-46 and DASA-
58, Tamoxifen-treated BMDMs derived from conditional
PKM2fl/fl-deficient mice were treated with TEPP-46 prior to
LPS and relative IL-1b expression was measured (Figure 5G).
LPS-induced Il1b expression was attenuated in PKM2-ablated
cells, with no further inhibitory effect observed following pre-
treatment with TEPP-46 or DASA-58.
Activation of PKM2 Using TEPP-46 Modulates the Anti-
Mycobacterium tuberculosis Response of Macrophages
To extend our investigations into PKM2 beyond LPS to an infec-
tious agent that utilizes TLRs other than TLR4, we next examined
a bacterial pathogen, Mycobacterium tuberculosis (Mtb). As the
main causative agent of tuberculosis,Mtb signalsmainly through
TLR 2, 6, and 9 (Bafica et al., 2005; Means et al., 1999).
Resting BMDMswere stimulated with FSL-1, a ligand for TLR2
and TLR6 or the TLR9 ligand CpG (Figure 6A) for up to 24 hr.ell Metabolism 21, 65–80, January 6, 2015 ª2015 Elsevier Inc. 71
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Figure 4. Activation of PKM2 Counteracts LPS-Induced Excessive Rate of Glycolysis and Restores Cellular Levels of Succinate
(A) Rate of glycolysis in BMDMs treated ±TEPP-46 (50 mM) or DASA-58 (50 mM) ±LPS.
(B) Succinate levels in LPS-treated BMDMs ± DASA-58 (50 mM) represented as relative abundance.
(C) Schematic map illustrating key metabolites and genes that were significantly enhanced (red) or inhibited (blue) in LPS-treated (100 ng/ml, 24 hr) BMDMs ±
50 mM DASA-58. All metabolites with significant accumulation (p value < 0.05) are shown in bold red text. Those in yellow suggest upregulation specific to LPS
stimulation. Statistical analysis performed on three separate experiments. Metabolites with p value < 0.05 and fold-change > 10%were deemed to be statistically
significant.Similarly to LPS, these ligands induced expression of PKM2 both
at protein level (Figure 6A) and mRNA level (Figure 6B). In addi-
tion, both FSL-1 and CpG induced pro-IL-1b and Hif-1a protein
expression (Figure 6A). Activation of PKM2 using TEPP-4672 Cell Metabolism 21, 65–80, January 6, 2015 ª2015 Elsevier Inc.significantly inhibited FSL-1 and CpG-induced Il1b mRNA
expression (Figure 6C).
We next turned to intact heat-inactivated Mtb as a stimulus.
Results from BMDMs treated with Mtb for 24 hr revealed an
A B C
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Figure 5. Inhibition of LPS-Induced Hif-1a and Hif-1a Target Genes in PKM2-Depleted BMDMs
(A–D) BMDMs from mice carrying a PKM2fl/fl allele and relative PKM2+/+ controls were treated with ±600 nM Tamoxifen (72 hr), followed by LPS (24 hr). Relative
mRNA expression levels of Pkm2 (A), Pkm1 (B), Il1b, and Ldha (D) were measured by qRT-PCR. PKM2, PKM1, Hif-1a, and b-actin protein expression was
measured by western blotting (C).
(E) IL-6 and TNFa protein measured by ELISA, depicted as means ± SD of results from triplicate determinations for one representative experiment, n = 2.
(F) Rate of glycolysis (left) and oxidative phosphorylation (right) in ethanol- (PKM2+/+) and Tamoxifen- (PKM2/) treated LPS-activated BMDMs derived from
PKM2fl/fl mice, measured as ECAR and OCR ± SD (n = 5).
(G) BMDMs derived from PKM2fl/fl mice treated with ethanol (PKM2+/+) or Tamoxifen (PKM2/) followed by TEPP-46 or DASA-58 (30 min) and LPS (24 hr) as
indicated. The cells were lysed and expression of il1b mRNA was determined by qRT-PCR.
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upregulation of PKM2 protein (Figure 6D, third panel, compare
lanes 1 and 2) as well as PKM2 mRNA (Figure 6E). In addition,
TEPP-46 inhibited Mtb-induced pro-IL-1b and Hif-1a protein,
(Figure 6D), as well as TNFa and IL-6 (Figure 6G), while signifi-
cantly boosting Mtb-induced IL-10 (Figure 6F). This result
indicates an important role for PKM2 in innate immune host re-
sponses originating from Toll-like receptors other than TLR4.
In a model of macrophage infection using live Mtb (strain
H37Ra), TEPP-46 inhibited Mtb-induced Il1b mRNA levels,
boosted Mtb-induced levels of Il10 mRNA, and had no effect
on levels of Tnf (Figure 6H). In addition, Mtb-induced IL-1b, but
also TNFa, protein levels were inhibited by TEPP-46, whereas
IL-10 protein was significantly increased by activation of PKM2
(Figure 6I).
While no significant differences were observed in bacterial
uptake 3 hr postinfection, Figure 6J shows an increased level
of intracellular bacteria at 72 hr postinfection in TEPP-46-
treated,Mtb-infected BMDMs compared toMtb infection alone.
These data are consistent with IL-10 promoting pathogen persis-
tence by contributing to Mtb phagosome maturation block
(O’Leary et al., 2011).
As illustrated in Figure 6K, BMDMs derived from IL-1 type I re-
ceptor knockout mice when infected with Mtb display an
increased bacterial load compared to wild-type cells, with no
effect of TEPP-46, demonstrating the requirement for intact
IL-1 autocrine signaling for efficient bacterial killing.
Activation of PKM2 Results in Increased Bacterial
Dissemination in a Salmonella typhimurium Model of
Infection
Upregulation of aerobic glycolysis in macrophages during endo-
toxemia plays a central part in the pathology of this disease
(Tannahill et al., 2013). TEPP-46, but not DASA-58, is pharmaco-
kinetically validated in vivo (Anastasiou et al., 2012). TEPP-46
efficacy as a PKM2 activator had been verified using key
in vitro assays as discussed above. To investigate the protective
effects of activation of PKM2 in vivo, we gave mice TEPP-46
prior to an LPS challenge in a model of sepsis. As shown in Fig-
ure 7A, this dramatically reduced levels of pro-IL-1b produced by
the peritoneal cells of these mice, compared to LPS treatment
alone. Furthermore, administration of TEPP-46 prior to LPS re-
sulted in animals expressing less IL-1b in the serum (Figure 7B),
while IL-6 levels were the same as in the LPS-alone-treated
animals (Figure 7C). As observed in BMDMs, serum levels of
IL-10 (Figure 7D) were greatly increased in animals givenFigure 6. Activation of PKM2 Modulates Anti-Mycobacterial Macropha
(A and B) Cell lysates from FSL-1- and CpG- (24 hr) treated BMDMswere analyzed
mRNA by qRT-PCR (B).
(C) BMDMs pretreated with TEPP-46 (50 mM, 30 min) were activated using FSL-
(D–G) Expression levels of IL-1b, Hif-1a, PKM2, and b-actin protein (D), pkm2 m
BMDMs ± TEPP-46 (30 min) stimulated using heat-inactivated Mtb.
(H) BMDMs ± TEPP-46 (25 mM) were infected with liveMtb H37Ra (MOI 5 bacteria
analyzed (qRT-PCR). Data are mean ± SD for triplicate determinations, n = 2.
(I) BMDMs ± TEPP-46 (25 mM) were infected as above (3 and 72 hr). IL-1b (left),
infected cells.
(J) BMDMs from (I) were lysed and CFU/ml determined.
(K) BMDMs derived from wild-type or IL-1 type I receptor knockout cells were i
determined. Depicted as means ± SD of results from triplicate wells for one repre
with post hoc Bonferroni correction).
CTEPP-46 prior to the LPS challenge, compared to the control
group. This suggests that activation of PKM2 in vivo counteracts
the inflammatory effects of LPS, most likely through inhibiting
Warburg metabolism.
In order to further investigate the effect of TEPP-46 in a model
of infection, we used Salmonella typhimurium (strain UK-1) in an
in vitro model of infection. BMDMs were treated with TEPP-46
prior to infection with S. typhimurium; 4 hr postinfection intracel-
lular bacterial load was counted (Figure 7E). Cells treated with
TEPP-46 displayed an increased bacterial load probably due
to decreased bacterial killing by the cell.
We next used S. typhimurium in an in vivo model of infection.
Similarly to the results obtained from the LPS-induced model of
sepsis, peritoneal cells from mice treated in vivo with TEPP-46
prior to infection with S. typhimurium display a significant reduc-
tion in IL-1b protein expression levels (Figure 7F) 2 hr postinfec-
tion. Serum levels of IL-6 and IL-18 (Figure 7G) remained
unchanged in TEPP-46-treated animals compared to the control
group; however, once again serum levels of IL-10 were greatly
enhanced in animals that were given TEPP-46 prior to infection.
In order to measure bacterial dissemination, mice were intra-
peritoneally infected with S. typhimurium and sacrificed 24 hr
postinfection. Livers and spleens were extracted and log col-
ony-forming units (CFUs)/organ were determined as illustrated
in Figure 7H. The bacterial load in the spleens and in the livers
in animals given TEPP-46 prior to infection was significantly
increased. This is likely to be due to decreased bacterial killing
due to the ability of TEPP-46 to inhibit IL-1b production while
simultaneously promoting production of anti-inflammatory IL-10.
DISCUSSION
Inflammatory immune cells, such as ‘‘M1’’ type macrophages,
dendritic cells, or Th17 cells harbor many of the metabolic
changes displayed by tumor cells. This allows the host immune
system to support anabolic processes and meet the increased
demand for biosynthetic precursors required for mounting an im-
mune response. Central to the metabolic switch observed in
tumors is PKM2, which we now demonstrate also plays a key
role in the glycolytic switch occurring in LPS-activated macro-
phages. We demonstrate PKM2 upregulation and phosphoryla-
tion in an activated macrophage, with only a minor change in
PKM1 protein expression. As LPS induces formation of a
PKM2 and Hif-1a complex that can bind to the IL-1b promoter,
this points to a role for PKM2 as an important regulator ofge Responses
for PKM2, IL-1b, Hif-1a, or b-actin expression bywestern blotting (A) and pkm2
1 (100 ng/ml) and CpG (1 mg/ml) for 24 hr. il1b was analyzed by qRT-PCR.
RNA (E), IL-10 (F), TNFa, and IL-6 protein (G, left and right) were measured in
/cell, 3 hr) and gene expression of Il1b (left), tnf (middle), and Il10 (right) mRNA
TNFa (middle), and IL-10 (right) production were measured in supernatants of
nfected as for (H) above. Cells were lysed at 72 hr postinfection and CFU/ml
sentative experiment n = 2. *p < 0.05, **p < 0.01, ***p < 0.001 (two-way ANOVA
ell Metabolism 21, 65–80, January 6, 2015 ª2015 Elsevier Inc. 75
A B
C D E
F
G
H
(legend on next page)
76 Cell Metabolism 21, 65–80, January 6, 2015 ª2015 Elsevier Inc.
Hif-1a activity, and Hif-1a-dependent genes in host defense, as
previously described in hypoxia and cancer where nuclear
PKM2, with PHD3 acting as a cofactor, regulates the transcrip-
tional activity of Hif-1a (Luo et al., 2011).
In addition, using isoform-specific PKM2 conditional knockout
cells, we show that induction of PKM2 by LPS is critical for Hif-1a
stabilization, in agreement with previous studies demonstrating
a PKM2/Hif-1a complex targeting Hif-1a expression (Luo et al.,
2011). Hif-1a will also be stabilized by succinate inhibiting
PHDs, providing further regulation of Hif-1a.
Current data indicate that PKM2, when highly expressed, ex-
ists in an equilibrium of enzymatically inactive pyruvate kinase
dimers (or monomers), which can translocate into the nucleus
(Christofk et al., 2008; Hitosugi et al., 2009), and enzymatically
active tetramers, which are retained in the cytosol (Mazurek
et al., 2005). The pyruvate kinase activity of the tetramers can
be regulated by the concentration of the naturally occurring up-
stream glycolytic intermediate FBP (Ashizawa et al., 1991; Jurica
et al., 1998), serine (Chaneton et al., 2012), as well as by a multi-
tude of posttranslational modifications (Wu and Le, 2013)
including tyrosine phosphorylation. Activity is controlled by sta-
bilizing or destabilizing the tetramer (Hitosugi et al., 2009). Tyro-
sine phosphorylation of PKM2 at residue 105 will inhibit the
formation of a tetramer by dislodging the binding of FBP. This
event has been shown to be important for the Warburg effect
in hypoxia and cancer (Hitosugi et al., 2009). We have found
that this also occurs in LPS-activated macrophages, reflecting
the similarities in metabolic changes observed in cancer, and
suggesting a role for PKM2 in the Warburg effect in macro-
phages. This role was confirmed using PKM2-activating com-
pounds DASA-58 and TEPP-46. These well-characterized and
highly specific compounds bind PKM2, which then forms a tight
tetramer with PKM1-like kinetic properties, an event that is resis-
tant to inhibition by tyrosine phosphorylation. In addition to
relieving the buildup of glycolytic intermediates, evident from
the higher pyruvate kinase activity of the PKM2 tetramer (Anas-
tasiou et al., 2012), this process also prevents nuclear transloca-
tion and therefore decreases the expression of several Hif-1a
target genes such as Ldha (Luo et al., 2011). We show that acti-
vation of PKM2 by DASA-58 or TEPP-46 forces PKM2 to take on
a tetrameric form. This impairs the ability of the PKM2 and Hif-1a
complex to bind to the Hif-1amotif in the promoter of the known
Hif-1a target gene IL-1b (Peyssonnaux et al., 2007; Zhang et al.,
2006), thereby inhibiting the transcriptional activity of Hif-1a and
induction of IL-1b and conceivably other Hif-1a-dependent
genes in response to LPS. This validates a role for dimeric/mono-
meric PKM2 in LPS action here. Interestingly, the effects of acti-
vating PKM2 also extend into changing the polarizing phenotypeFigure 7. Activation of PKM2 In Vivo Diminishes the Host Immune Re
Infection
(A–D) Pro-IL-1b in PECs isolated from mice injected i.p. with TEPP-46 (50 mg/kg
PBS or 15mg/kg LPS for 2 hr (A). Left: one representative sample from each tr
five mice per group and treatment, normalized to b-actin. Serum levels of IL-1b (
**p < 0.01.
(E–G) BMDMswere treated ±TEPP-46 (30min, 25 mM), prior to infection with S. typ
assessed at 4 hr p.i. CFU/ml enumerated 4 hr after plating. Mice were injected ±TE
Pro-IL-1b from PECs was measured by western blotting (F), and serum levels of
(H) Mice were infected as in (F), and sacrificed 24 hr postinfection. Livers and s
mean ± SEM, two-tailed t test).
Cof a macrophage, with tetramerization of LPS-induced PKM2 in
an M1 macrophage-promoting characteristics typical of the M2
phenotype. This implies that the activation of PKM2 is a potential
therapeutic approach in inflammatory diseases.
Activation of PKM2 also inhibited induction of IL-1b and
boosted IL-10 production inMtb-infectedmacrophages promot-
ing bacterial growth. This extended our observation beyond
TLR4 and LPS to a bacterial pathogen that utilizes TLR2,
TLR6, and TLR9.
We demonstrated the impact tetramerization of PKM2 on
limiting the host immune response in vivo, by attenuating both
LPS and S. typhimurium-induced IL-1b while boosting IL-10,
leading to impaired clearance of infection evident from increased
bacterial dissemination. Our results are in agreement with the
study of Yang et al., who demonstrated that inhibition of PKM2
with shikonin prevented lethality in a model of septic shock,
although the mechanism of shikonin is not fully understood
(Yang et al., 2014).
We confirmed that LPS stimulation leads to accumulation
of upstream glycolytic intermediates, such as G6P, FBP,
DHAP, and 2-PG, and TCA cycle intermediates including
succinate (Tannahill et al., 2013). Activation of PKM2 using
DASA-58 dramatically reverts this glycolytic phenotype.
Coupled results of metabolomics and microarray analysis
further indicated PKM2-mediated metabolic reprogramming
of activated macrophages. The data indicate a combination
of transcriptional regulation of key enzymes to increase flux
into lactate, divert metabolites into the pentose phosphate
pathway, and thereby divert pyruvate away from the TCA cycle.
These events are all prevented by PKM2 activation by DASA-
58 and TEPP-46, which thereby prevent macrophage activation
by LPS.
Another consequence of the metabolic changes in LPS-acti-
vated macrophages is an increase in succinate. Activation of
PKM2 also limits this response and this will lead to Hif-1a desta-
bilization. From our data, the effect of PKM2 activation in terms
of pyruvate kinase activity on LPS-activated macrophages is
therefore 3-fold. First, it will limit the nuclear function of PKM2
and decrease Hif-1a-dependent gene expression. Second, the
decrease in succinatewill further limit Hif-1a through stabilization
and degradation. Finally, it will decrease levels of glycolytic
and pentose phosphate pathway metabolites, thereby limiting
biosynthesis. The increased pyruvate kinase activity of PKM2
will also increase the flux of pyruvate into the TCA cycle. This
could explain the increase in IL-10 production, which in the
case of M2 macrophage activity may require mitochondrial
oxidative metabolism (Krawczyk et al., 2010). Precisely how
PKM2 promotes IL-10 production requires further analysis.sponse in LPS-Induced Sepsis and in an S. typhimurium Model of
) or vehicle control (20% 2-Hydroxypropyl-b-cyclodextrin) for 1 hr, followed by
eatment group. Right: densitometry readings of pro-IL-1b western blots from
B), IL-6 (C), and IL-10 (D) from mice in (A). n = 5 for each group, mean ± SEM,
himuriumUK-1 strain at anMOI of ten bacteria/cell (E). Bacterial numbers were
PP-46 (50mg/kg), 1 hr prior to infection withS. typhimurium (13 106 CFU, 2 hr).
IL-6, IL-10, and IL-18 were measured by ELISA (G).
pleens were extracted and Log CFU/organ was determined (n = 5 per group,
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PKM2 in its dimeric, catalytically less active form is therefore
required for glycolytic reprogramming in response to LPS, most
likely because of the role dimeric PKM2 plays in Hif-1a function.
In conclusion, we have revealed a role for PKM2 in LPS-
induced activation of macrophages and in macrophages in-
fected with Mtb, as well as in an in vivo S.typhimurium model
of infection providing important insights into the Warburg-like
metabolic changes in macrophages, likely to be very important
for inflammation and infection. Targeting PKM2 in order to inhibit
glycolysis or re-engaging mitochondrial oxidative metabolism in
an overactive macrophage may provide novel therapeutic
approaches for inflammatory diseases.
EXPERIMENTAL PROCEDURES
Reagents
TEPP-46 and DASA-58 were synthesized in accordance with published
methods (Boxer et al., 2010; Jiang et al., 2010). LPSs used in vitro
(100 ng/ml) and in vivo were E. coli, serotype EH100 (Alexis), and 055:B5
(Sigma-Aldrich). 4-hydroxytamoxifen (H7904) was from Sigma. The fol-
lowing antibodies were used: anti-PKM2 (3198), antiphospho-PKM2
(Tyr105), b-actin (4267) (all Cell Signaling Technologies), anti-IL-1b (R&D,
AF401-NA), anti-HIF-1a (Novus, NB100-449), and anti-PKM1 (Novus, NBP2-
14833). Dimethyl sulfoxide (DMSO) was used as vehicle control for TEPP/
DASA in all in vitro assays.
Mice and Cell Culture
BMDMs and PECs were isolated from C57BL/6 mice from Harlan UK as pre-
viously described (Tannahill et al., 2013). All experiments were carried out with
prior ethical approval from Trinity College Dublin Animal Research Ethics
Committee. Cells were used at 1 3 106 cells/ml unless otherwise stated.
Each ‘‘n’’ represents BMDM/PECs from individual mice.
BMDMs from mice carrying a PKM2fl/fl allele were previously described
(Israelsen et al., 2013). Ablation of PKM2 was achieved by adding 600 nM
4-hydroxytamoxifen (Sigma H7904) on day 4 of macrophage differentiation,
until 24 hr prior to experiment.
Western Blotting
Western blot analysis was carried out as previously described (Fitzgerald et al.,
2001). Western blots were developed using autoradiographic film or using a
Gel Doc EZ System gel imaging system, alternatively.
RNA Isolation and Gene Expression
RNA was transcribed using High-Capacity cDNA Reverse Transcription Kit
(Applied Biosystems). For mRNA, 18 s ribosomal RNA or RPS18 gene were
used as housekeeping controls. Relative quantitation values were calculated
using the 2(-Delta Delta C(T)) method (Livak and Schmittgen, 2001).
Nuclear and Cytosolic Fractionation
Nuclear Extract Kit (Active Motif, 40010) was used according to manufac-
turer’s recommendations; 20 ml of each fraction was separated by SDS-
PAGE prior to western blotting.
Crosslinking
BMDMs or RAW264.7macrophageswere treatedwith 50 mMTEPP-46, 20 mM
DASA-58 or DMSO. Crosslinking was performed using 500 mM disuccinimidyl
suberate (Thermo Scientific Pierce) for 30 min. Lysates were analyzed by
western blot.
Size Exclusion Chromatography
We loaded 2–3 mg protein from RAW 264.7 ± 10 mM TEPP-58 or DMSO (1 hr),
followed by 100 ng/ml LPS (24 hr) on a Superdex 200 10/300GL column (GE
Healthcare) and eluted with 50 mM sodium phosphate, 150 mM NaCl
(pH7.5). We took 250 ml fractions and analyzed them by SDS-PAGE and west-
ern blot.78 Cell Metabolism 21, 65–80, January 6, 2015 ª2015 Elsevier Inc.ELISA
ELISAs were performed according to manufacturers’ instructions. Kits used
were IL-1b (DY401), IL-6 (DY406), IL-10 (DY417), TNFa (DY410), and IL-1b
(MLB00C, in vivo), IL-10 (M1000B, in vivo) (all from R&D). Results are pre-
sented as mean ± SEM. Two-tailed t tests were carried out.
Microarray Profiling and Measurement of LC-MS
Microarray and metabolomics profiling were performed as described in
Tannahill et al. (2013).
Statistical Analysis of Microarray Data
Statistical analysis of microarray data was carried out in MATLAB. Data were
checked for correlation between replicates (>0.96 on average within groups).
Probeswithout any gene assignmentswere removed and further filtered on the
basis of having a variance, signal, or entropy less than tenth percentile of the
entire dataset. Remaining probes were analyzed for statistically significant dif-
ferences (fold-change > 25%) between three groups (two-tailed t test
assuming equal variance). We identified 107 probes (100 genes) as statistically
significant across the three groups. p values were corrected for multiple hy-
pothesis testing by Benjamini-Hochberg’s method to control false discovery
rate at 25%.
Coimmunoprecipitation
BMDMs (±LPS, 24 hr) were lysed as previously described (Fitzgerald et al.,
2001). PKM2 immune complexes were precipitated using anti-PKM2 antibody
coupled to protein A/G PLUS agarose beads (Santa Cruz Biotechnology) for
2 hr at 4C. Nonspecific rabbit IgG antibody was used for control. Immunopre-
cipitated proteins were visualized by western blotting using anti-PKM2 or
Hif-1a antibodies respectively. Lysates were blotted for PKM2 and Hif-1a to
control for input.
Affinity Purification with Biotinylated Oligonucleotides
Oligonucleotides for the HIF1a binding site on the IL1b promoter were
annealed as described (Quinn et al., 2014) (forward, 50BIO-GGT AGG CAC
GTA GAT GCA CAC C-30; reverse, 50-GGT GTG CAT CTA CGT GCC TAC
C-30). BMDMs (0.5 3 106 cell/ml) were treated with DASA (50 mM) or TEPP
(100 mM) for 1 hr prior to LPS (24 hr). Oligonuceotide pull-down was performed
as previously described (Quinn et al., 2014).
Chromatin Immunoprecipitation
BMDMs (0.5 3 106 cell/ml) were treated ±DASA-58 or TEPP-46 (1 hr) prior
to LPS treatment for 24 hr. ChIP was performed as previously described
(Quinn et al., 2014; Tannahill et al., 2013). Lysates were incubated with
primary antibodies; Anti-HIF-1-a antibody (Abcam, ab2185), negative
control anti-IgG (Sigma, I5006), and positive control Pol II Antibody (Santa
Cruz Biotechnologies [N20] sc-899). For Sequential ChIP, the precipitated
HIF1a sample was reprobed for binding of PKM2 (2 hr incubation, 30 ml
preblocked Protein A/G beads, 30 ml PKM2 D78AXP antibody [4053]).
qRT-PCR was carried out using primers for the IL1b promoter consensus
HIF1a binding site (408), or the b-actin promoter as a positive control
for Pol II binding (data not shown). Data are calculated as percent of
input and represented by one experiment expressed as fold binding
(n = 3, ± SD).
Extracellular Acidification and Oxygen Consumption Rate
XF24 Extracellular Flux analyzer (Seahorse Biosciences) was used. BMDMs
were plated at 200,000 cells/well in XF24 plates overnight then ± 50 mM
TEPP-46 or DASA-58 (1 hr), followed by LPS for 24 hr. Results were normalized
to cell number and are represented as mean ± SEM.
Statistical Analysis of Metabolomics Data
Processed data was log transformed (base 2). Correlation between replicates
were >0.94 on average within different treatment groups. Significance was as-
sessed using a two-tailed t test (assuming equal variance) and metabolites
with fold-change > 10% were selected. Metabolites scoring with nominal
p value < 0.05 across any of the four comparisons were selected for further
analysis.
Mycobacterium Tuberculosis Assays
Infections were carried out at an MOI of 5 Mtb H37Ra/macrophage. For
RNA analysis, cells were lysed in Trizol Reagent (Invitrogen). ELISA results
are shown as means ± SEMs for one representative experiment n = 2. *p <
0.05, **p < 0.01, ***p < 0.001 (two-way ANOVA with post hoc Bonferroni
correction).
In Vitro Uptake Assay
Serial dilutions of lysates from BMDM ± TEPP-46 infected with S. typhimurium
strain UK-1 (MOI 10 bacteria/cell) were quantified as CFU/ml. Data are shown
as mean ± SEM for three independent infections.
Endotoxin-Induced and S. typhimurium In Vivo Model of Sepsis
Mice were treated ± TEPP-46 (50 mg/kg) or vehicle (20% 2-Hydroxypropyl-
b-cyclodextrin) i.p. for 1 hr; 15 mg/kg of LPS, alternatively 1 3 106 CFU
S. typhimurium was administered i.p.; 2 hr postinfection serum was isolated
from whole blood and PECs were harvested.
To measure bacterial dissemination, we sacrificed mice infected as above
24 hr postinfection. Log CFU/liver alt spleen was determined.
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